Working… Menu

Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00005096
Recruitment Status : Completed
First Posted : March 4, 2004
Last Update Posted : July 14, 2017
National Cancer Institute (NCI)
Rhone-Poulenc Rorer
Information provided by (Responsible Party):
Mary-Ellen Taplin, MD, Dana-Farber Cancer Institute

Brief Summary:

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of docetaxel in treating patients who have stage II or stage III prostate cancer.

Condition or disease Intervention/treatment Phase
Prostate Cancer Drug: docetaxel Phase 2

Detailed Description:

OBJECTIVES: I. Determine the pathologic complete response rate to docetaxel in patients with high risk stage II or III prostate cancer. II. Determine the toxicity of this treatment in these patients. III. Correlate clinical measures of response (e.g., symptoms, physical exam, serum PSA, and endorectal MRI) with pathologic response to this treatment in these patients.

OUTLINE: Patients receive docetaxel IV over 30 minutes weekly for 4 weeks. Treatment continues for 2-6 courses in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A total of 19-45 patients will be accrued for this study over 18 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 19 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer
Actual Study Start Date : December 1999
Actual Primary Completion Date : June 2002
Actual Study Completion Date : June 2002

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer
Drug Information available for: Docetaxel

Arm Intervention/treatment
Experimental: Docetaxel
Docetaxel given via iv at determined dose once a week for 4 weeks
Drug: docetaxel
Other Name: Taxotere

Primary Outcome Measures :
  1. Complete Response Rate [ Time Frame: 2 Months, 6 Months ]
    Wilcoxon Signed Rank Test

Secondary Outcome Measures :
  1. Percentage of Participants with mild to moderate toxicity [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Eligibility Criteria:

  • Histologically confirmed adenocarcinoma of the prostate
  • Potential candidate for radical prostatectomy
  • Any of the following:

    • Clinical stage T3 patients
    • Serum PSA at least 20 ng/mL
    • Gleason score 8-10
    • Clinical T2 disease and either of the following:

      • MRI evidence of seminal vesicle involvement
      • Gleason 4+3 cancer with either 5 or 6 biopsies positive
  • CALGB 0-1
  • WBC greater than 3,000/mm3
  • Hematocrit greater than 30%
  • Platelet count greater than 100,000/mm3
  • SGOT, total bilirubin within normal limits
  • Signed Informed consent

Exclusion Criteria:

  • No prior hormones, radiation or chemotherapy for prostate cancer
  • Evidence of serious active infection

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00005096

Layout table for location information
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02115
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
Rhone-Poulenc Rorer
Layout table for investigator information
Principal Investigator: Mary-Ellen Taplin, MD Dana-Farber Cancer Institute

Layout table for additonal information
Responsible Party: Mary-Ellen Taplin, MD, Taplin, Mary-Ellen, Dana-Farber Cancer Institute Identifier: NCT00005096     History of Changes
Other Study ID Numbers: 99-193
P30CA006516 ( U.S. NIH Grant/Contract )
First Posted: March 4, 2004    Key Record Dates
Last Update Posted: July 14, 2017
Last Verified: July 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Mary-Ellen Taplin, MD, Dana-Farber Cancer Institute:
adenocarcinoma of the prostate
stage II prostate cancer
stage III prostate cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action